Journal article
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Abstract
BACKGROUND: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. METHODS: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes …
Authors
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS
Journal
Lancet (London, England), Vol. 389, , pp. 1399–1409
Publication Date
2017
DOI
10.1016/S0140-6736(17)30069-7
ISSN
1474-547X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultBlood GlucoseBody Mass IndexBody WeightDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsIncretinsInjections, SubcutaneousLiraglutideMaleMiddle AgedObesityPlacebosPrediabetic StateRisk Reduction BehaviorTreatment OutcomeWeight LossGlucagon-Like Peptide-1 Receptor Agonists